A new Australian study, using the Swedish instrument Nevisense, showed it is possible to reduce the number of cases that require digital dermoscopy follow-up by almost half. In addition Nevisense detected most melanoma three months earlier than traditional methods. Nevisense thereby constitutes a valuable complement to a visual exam with a dermatoscope. The study consisted of 118 patients with 160 lesions, and the results will be presented for the first time at the World Congress on Cancers of the Skin in Vienna on September 1. Malignant melanoma is often difficult to detect, and early detection is of crucial importance. Lesions suspected of being malignant melanoma, but which cannot be clearly determined during the initial examination, are followed up in many cases with the help of what is known as short term digital dermoscopy imaging (SDDI), which means that the lesion is photographed and compared over time. The use of SDDI is increasing – especially in difficult-to-diagnose cases – but it is resource-intensive and can take three months or more for a final diagnosis. In addition, it can be challenging to get patients to return for follow-up visits. In the new Australian study, conducted by Dr Lilian Rocha, Associate Prof. Pascale Guitera, Prof. Scott W. Menzies et. al. at the Melanoma Institute of Australia and Royal Prince Alfred Hospital in Sydney, SDDI was combined with Nevisense’s electrical impedance spectroscopy (EIS) measurement with the following results: · 19% of all examined lesions showed a Nevisense EIS value of seven or more and were surgically removed immediately. 83.1% of the malignant melanoma in the study was discovered by Nevisense three months earlier than what SDDI would have allowed. · 28% showed a Nevisense EIS value of three or less, which would have made the need for a patient follow-up visit unnecessary. · The combination of SDDI and Nevisense detected 100% of all malignant melanoma in the study. In total, the use of Nevisense showed the potential to reduce the number of cases that needed to undergo SDDI by 47%. This could simplify diagnostics and lead to significant cost savings for health care while shortening patients’ waiting time for a diagnosis. “The cases in the study involve difficult-to-diagnose lesions, and the current diagnostic process is time consuming for both clinicians and patients. This study result is very important because it shows the potential for Nevisense to improve the process - saving both time and resources in the healthcare sector” says Simon Grant, CEO at SciBase. For more information, please contact: Simon Grant, CEO Phone: +46 72 887 43 99 Email: simon.grant@scibase.com This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10.00 CET on August 26, 2016. About Skin Cancer Skin cancer is one of the most common cancers in the world, accounting for nearly half of all cancers. It has been estimated that nearly half of all Americans who live to the age of 65 will develop skin cancer at least once. Malignant melanoma is the most fatal form of skin cancer causing the majority (75%) of deaths related to skin cancer. Worldwide, doctors diagnose about 230,000 new cases of melanoma yearly. About SciBase and Nevisense SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and is awaiting FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”). Avanza is the certified advisor. Further information is available on www.scibase.com.
New Study: Swedish Nevisense can reduce follow-up visits by
Top 10 Most Recent News Articles
Stardock Fences 7 Targets Messy Windows Desktops Everywhere
A cluttered Windows desktop is a tiny tax on attention, and Stardock has spent three decades selling people a way around it. Fences 7, released November 18, 2026, is the latest swing: a Windows 11-focused update that combines cosmetic polish with a genuinely practical privacy feature. This is not grand enterprise software, and nobody should pretend a $10 desktop utility...
Continue Reading
Texas Restaurants Get a New Read on Customer Demand
Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...
Continue Reading
Cold-Season Cleaning Advice Has a Practical Catch!
Remote Controls Are Nobody’s First Suspect A television remote can make the rounds all evening and never see a cloth, which is precisely why Maid Brigade’s cold-and-flu-season reminder lands as common sense rather than revelation. The Scottsdale cleaning company is telling households to look past the usual kitchen counter and bathroom sink routine. Fair enough. People...
Continue Reading
Fox Hill Steel Marks a Long Public-Building Road Ahead
A signed steel beam is a fine civic moment, but it is not the finish line. Burlington’s new Fox Hill Elementary School has reached its topping-off milestone, with the structural steel now in place for a 91,000-square-foot, two-story facility intended to serve roughly 325 kindergarten-through-fifth-grade students. That is tangible progress, the sort nobody can fake with...
Continue Reading
Radiology Staffing Gap Deepens as Imaging Demand Rises
An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...
Continue Reading
Fapon’s Enzyme Push Meets Diagnostics Reality at AMP
Enzymes rarely get applause at industry meetings, but they can quietly decide whether a diagnostic workflow behaves or becomes a lab headache. Fapon used its AMP 2026 appearance in Seattle to make that unglamorous case: better enzyme design may help assays move faster and keep working when samples get messy. The company wrapped up the November 10–14 meeting after...
Continue Reading
Commodity Rout Tests a Market Already Short on Nerve
Some weeks the tape merely wobbles; this one started throwing furniture. By midday Wednesday, traders were staring at sharp declines in gold, silver, crude and copper while the major equity benchmarks remained underwater for the week. That is an unpleasant combination. When growth-sensitive commodities and the usual hard-asset hiding places are all getting sold,...
Continue Reading
Pressure Injury Care Needs More Than Awareness Alone
Wet skin does not care how polished the awareness campaign looks. That is the uncomfortable truth sitting underneath Worldwide Pressure Injury Prevention Day, the annual observance held on the third Thursday of November. Pressure injuries remain a stubborn problem across healthcare facilities and home care settings because prevention is not one tidy action; it is a chain...
Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care
Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...
Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion
Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...
Continue ReadingTop 5 Most Recently Viewed Articles
Petrus Resources Announces Exciting Monthly Dividend Update
Petrus Resources Monthly Dividend Declaration Petrus Resources Ltd. (TSX: PRQ) is excited to share that its Board of Directors has declared a new monthly dividend. This dividend is set at $0.01 per share and is designated for the shareholders of record. The scheduled payment date is set for December 30, and this announcement comes with important information for...
Continue Reading
Important Update for Sprinklr Investors: Know Your Rights
Key Update for Sprinklr Investors Investors who have experienced losses exceeding $100,000 in Sprinklr, Inc. should take a moment to examine their rights as shareholders. Faruqi & Faruqi, LLP, a well-regarded national securities law firm, is currently investigating possible claims against Sprinklr, which is listed on the NYSE under the ticker CXM. The firm is available to...
Continue Reading
Collaborative Innovations in Multi-Omics Data Management
DNAnexus and Panomics Unite for Biopharma Excellence In the ever-evolving landscape of biopharma, data plays a pivotal role in shaping advancements and innovations. DNAnexus, a leader in precision health data management, and Panomics, renowned for AI-powered omics data discovery, have announced a collaborative initiative aimed at revolutionizing how biopharma...
Continue Reading
WisdomTree Investors May Have Claims to Explore: Pomerantz Insights
Pomerantz Investigates Potential Investor Claims Pomerantz LLP is currently investigating claims on behalf of investors of WisdomTree, Inc. (NYSE: WT). This investigation suggests a focus on the possibility of securities fraud or other unlawful business practices that may involve the Company's officers or directors. Insights on WisdomTree's Recent Challenges Recent...
Continue Reading
Introducing ROADSAVER: A Breakthrough in Carotid Stenting
Announcing the ROADSAVER Carotid Stent System Terumo Interventional Systems (TIS) is thrilled to announce the early commercial availability of the ROADSAVER™ Carotid Stent System. This FDA-approved device is specifically designed for patients with carotid artery stenosis, aiming to reduce complications that may arise after carotid endarterectomy. With the integration of...
Continue Reading